Fidaxomicin
Fidaxomicin is an orphan drug that treats Clostridium difficile infections. This drug inhibits bacterial RNA polymerase and cause rapid death of C. difficile bacteria. It undergoes minimal systemic absorption and causes its effects directly in the GI tract. C. difficile is a sporeforming, anaerobic bacillus that transmitted to human via the fecal-oral route. The FDA-approved dosing of fidaxomicin is 200 mg twice daily for 10 days with or whithout food for adults. The most common adverse effects of this drug are gastrointestinal events like vomiting, nausea, gastrointestinal hemorrhage, and abdominal pain.